DELRAY BEACH, Fla., April 2, 2025 /PRNewswire/ -- The global US Clinical Trial Services Market is expected to reach US$39.61 billion by 2030 from US$25.57 billion in 2025, at a CAGR of 9.2% during the forecast period. The growth in the US clinical trial services market is fueled by various factors, such as a well-established pharmaceutical industry, increased demand for clinical trials, high R&D expenditure, and the rising outsourcing of clinical and laboratory testing services by market players.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=405

Browse in-depth TOC on "US Clinical Trial Services Market"

163 - Tables
62 – Figures
220 – Pages

The small molecules segment accounted for the largest share of the US clinical trial services market by modality during the forecast period.  

Based on modality, the US clinical trial services market is divided into small molecules, biologics, and medical devices. The small molecule segment holds a dominant share of the US clinical trial service market. Cost efficiency, streamlined development timelines, proven clinical success rates coupled with strong demand for targeted therapies, oral drugs, and generics reinforce their commercial viability and long-term market leadership and are contributing to the growth of the segment.

The oncology subsegment accounted for the largest share of the US clinical trial service's therapy area segment in 2024.

Based on therapy area, the US clinical trial services market is segmented into oncology, neurology, infectious diseases, cardiovascular system (CVS) disorders, metabolic disorders/endocrinology, immunological disorders, respiratory disorders, psychiatry, dermatology, hematology, ophthalmology, gastrointestinal diseases, genitourinary & women's health, and other therapeutic areas. In 2024, the oncology segment dominated the US clinical trial services market. The increase in cancer cases due to aging populations and lifestyle factors, supported by rising demand for new treatments, high commercial potential of oncology drugs, and the growing adoption of biomarker-driven trials, have bolstered the prominence of the oncology segment.

The phase III segment is expected to account for the largest share of the phase segment in the US clinical trial services market in 2024.

Based on phase, the US clinical trial services market is segmented into Phase I, Phase II, Phase III, and Phase IV. The Phase III segment is likely to grow at a faster CAGR during the forecast period of 2024-2029. High patient enrolment, significant financial investment, and increasing complexity in oncology, neurology, and rare disease trials have fueled the growth of the phase III segment.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=405

Key players in the US clinical trial services market include IQVIA Inc. (US), Thermo Fisher Scientific Inc. (US), Fortrea (US), Syneos Health (US), Laboratory Corporation of America Holdings (US), Medpace (US), Frontage Labs (US), Pharmaron (US), Parexel International Corporation (US), Worldwide Clinical Trials (US), Allucent (US), Premier Research (US), Clario (US), KCR S.A. (US), Rho, Inc. (US) and Advanced Clinical (US) among others.

Study Coverage:

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the US clinical trial services market. A detailed analysis of the key industry players has been done to provide insights into their business overviews; service offerings; key strategies; acquisitions, new service launches, expansions, agreements, and recent developments associated with the US clinical trials services market.

For more information, Inquire Now!

Related Reports:

Cancer Biomarkers Market

Cancer Profiling Market

Exosome Research Market

Next Generation Sequencing Market

Multiplex Assays Market

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

In addition, MarketsandMarkets SalesIQ enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/

Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/us-clinical-trial-services-market-worth-us39-61-billion-by-2030-with-9-2-cagr--marketsandmarkets-302418054.html

SOURCE MarketsandMarkets